Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Deflazacort. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.95 |
| ▸ | PGR | P06401 | 7/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | IL5 | P05113 | 1/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deflazacort SCHEMBL4019 | 0.98 | NR3C1 (1.00) | NR3C1PGRHIF1ACYP3A4LMNA | |
| Deflazacort SCHEMBL24497637 | 0.98 | NR3C1 (1.00) | NR3C1PGRHIF1ACYP3A4LMNA | |
| Deflazacort SCHEMBL4018 | 0.98 | NR3C1 (1.00) | NR3C1PGRHIF1ACYP3A4LMNA | |
| Deflazacort SCHEMBL2598076 | 0.98 | NR3C1 (1.00) | NR3C1PGRHIF1ACYP3A4LMNA | |
| Deflazacort SCHEMBL22502722 | 0.97 | NR3C1 (0.98) | NR3C1PGRHIF1ACYP3A4LMNA | |
| Deflazacort SCHEMBL17941674 | 0.95 | NR3C1 (0.94) | NR3C1PGRHIF1ACYP3A4LMNA | |
| Deflazacort SCHEMBL887173 | 0.91 | NR3C1 (0.84) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL13653579 | 0.90 | NR3C1 (0.86) | NR3C1PGRHIF1ACYP3A4LMNA | |
| 21-Desacetyldeflazacort SCHEMBL30754690 | 0.89 | NR3C1 (0.81) | NR3C1PGRHIF1ACYP3A4LMNA | |
| SCHEMBL13653592 | 0.87 | NR3C1 (0.80) | NR3C1PGRHIF1ACYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101132766-A | Tablet containing steroid hormone | LOHMANN THERAPIE SYST LTS (DE) | 2008-02-27 | — | — | CN | claimed |
| EP-1470227-B1 | Method for selective introduction of a double bond in a steroid | BAYER SCHERING PHARMA AG (DE) | 2007-04-11 | — | — | EP | claimed |
| US-20060222708-A1 | Wafer comprising steroid hormones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-10-05 | — | — | US | claimed |
| US-20040091987-A1 | Process for the overexpression of dehydrogenases | SCHERING AG (DE) | 2004-05-13 | — | — | US | claimed |
| CN-104983669-B | tablet containing steroid hormone | LTS勒曼治疗系统股份公司 | 2018-05-18 | — | — | CN | disclosed |
| US-20170348321-A1 | Wafer Comprising Steroid Hormones | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2017-12-07 | — | — | US | disclosed |
| US-9763960-B2 | Wafer comprising steroid hormones | LTS LOHMANN THERAPLE-SYSTEME AG (DE) | 2017-09-19 | — | — | US | disclosed |
| CN-104983669-A | TABLET CONTAINING STEROID HORMONES | LOHMANN THERAPIE SYST LTS | 2015-10-21 | — | — | CN | disclosed |
| US-20090075328-A1 | PROCESS FOR THE OVEREXPRESSION OF DEHYDROGENASES | SPELLIG TILMAN | 2009-03-19 | — | — | US | disclosed |
| US-7416866-B2 | Process for the overexpression of dehydrogenases | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| CN-101132766-A | Tablet containing steroid hormone | LOHMANN THERAPIE SYST LTS (DE) | 2008-02-27 | — | — | CN | disclosed |
| US-20060222708-A1 | Wafer comprising steroid hormones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20040091987-A1 | Process for the overexpression of dehydrogenases | SCHERING AG (DE) | 2004-05-13 | — | — | US | disclosed |
| EP-0876394-B1 | PREPARATION OF (11BETA,16BETA)-21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-5'H-PREGNA-1,4-DIENO 17,16-D]OXAZOLE-3,20-DIONE | LEPETIT SPA (IT) | 2001-05-16 | — | — | EP | disclosed |
| US-6103895-A | ESTERIFICATION OF 21-DEACETYL FLAZACORT WITH ACETIC ANHYDRIDE IN AQUEOUS SOLUTION CONTAINING ORGANIC SOLVENT AND BASIC CATALYST, RECOVERING FLAZACORT | GRUPPO LEPETIT S.P.A. (IT) | 2000-08-15 | — | — | US | disclosed |
| EP-0876394-A1 | PREPARATION OF (11$g(b),16$g(b))-21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-5'H-PREGNA-1,4-DIENO 17,16-D]OXAZOLE-3,20-DIONE | GRUPPO LEPETIT S.p.A. (IT) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997021722-A1 | PREPARATION OF (11β,16β)-21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-5'H-PREGNA-1,4-DIENO[17,16-D]OXAZOLE-3,20-DIONE | GRUPPO LEPETIT S.P.A. (IT) | 1997-06-19 | — | — | WO | disclosed |